Alpha Synuclein Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Alpha-synuclein (SNCA) is a small, natively unfolded protein that plays critical roles in synaptic function and is central to the pathogenesis of Parkinson's disease and related neurodegenerative disorders. As the major component of Lewy bodies, pathological aggregates of alpha-synuclein are a hallmark of several neurodegenerative diseases collectively termed synucleinopathies.
Alpha-synuclein is a 140-amino acid protein encoded by the SNCA gene on chromosome 4q21. The protein comprises three distinct domains:
N-terminal domain (residues 1-60): Contains seven imperfect repeats of the sequence KTKEGV, which form an amphipathic alpha-helical structure upon membrane binding. This region is highly conserved and mediates lipid interactions.
NAC region (residues 61-95): The Non-Aβ Component (NAC) of amyloid plaques contains the hydrophobic core responsible for aggregation propensity. This region is essential for fibril formation.
C-terminal domain (residues 96-140): Acidic and proline-rich, this region exhibits chaperone-like activity and is involved in protein-protein interactions. It modulates aggregation kinetics.
The SNCA gene produces multiple splice variants:
Post-translational modifications including phosphorylation at Ser129, ubiquitination, nitration, and oxidation significantly impact aggregation propensity and pathological properties.
Alpha-synuclein is highly enriched in presynaptic terminals where it regulates:
The N-terminal domain binds to curved membrane surfaces, particularly synaptic vesicles. This interaction is thought to:
Alpha-synuclein aggregation follows a nucleation-dependent polymerization pathway:
Lewy bodies are intraneuronal inclusions composed of:
Soluble oligomeric intermediates are considered the most toxic species:
| Mutation | Location | Effect |
|---|---|---|
| A53T | Exon 3 | Early onset, rapid progression |
| A30P | Exon 3 | Reduced membrane binding |
| E46K | Exon 3 | Enhanced aggregation |
| H50Q | Exon 3 | Increased fibril formation |
| G51D | Exon 3 | Reduced aggregation |
| A53E | Exon 3 | Altered membrane interactions |
Common variants in the SNCA promoter (REP1 microsatellite) and 3' region influence expression levels and disease risk.
Alpha-synuclein interacts with numerous proteins:
The study of Alpha Synuclein Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-840. DOI:10.1038/42166
Braak H, Tredici KD, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211. DOI:10.1016/s0197-4580(0200065-9
Stefanis L. Alpha-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2(2):a009399. DOI:10.1101/cshperspect.a009399
Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14(2):467-475. DOI:10.1016/0896-6273(9590302-x
Conway KA, Lee SJ, Rochet JC, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to familial Parkinson's disease: a kinetic study. Proc Natl Acad Sci U S A. 2000;97(2):571-576. DOI:10.1073/pnas.97.2.571
Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011;108(10):4194-4199. DOI:10.1073/pnas.1100976108
Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364(9440):1167-1169. DOI:10.1016/s0140-6736(0417103-1
Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276(5321):2045-2047. DOI:10.1126/science.276.5321.2045
Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164-173. DOI:10.1002/ana.10795
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998;95(11):6469-6473. DOI:10.1073/pnas.95.11.6469
Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4(2):160-164. DOI:10.1038/ncb841
George JM. The synucleins. Genome Biol. 2002;3(1):reviews3002. DOI:10.1186/gb-2002-3-1-reviews3002